Denali Therapeutics Inc. (DNLI)
DNLINASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$20.30
+0.2000 (+1.00%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $3.26bn
- P/E
- –
- EPS, last 4 quarters
- $-2.74
- Dividend yield
- –
- Day range
- –
- 52-week range
- $13.75 to $27.30
- Average volume
- 1.76m
- Previous close
- $20.10
Analysts
11 coveringBuy11 buy, 0 hold, 0 sell
Targets a year out average $35.17, +73.3% from here
Earnings
next estimate $-0.6100Next report
Dec 2025
+2.7%
Mar 2026
+5.5%
Jun 2026
+5.6%
Sep 2026
+7.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | $3.60m | $17.78m |
| Gross profit | – | – | $3.51m | $17.59m |
| Operating income | -$137.37m | -$137.36m | -$130.54m | -$126.75m |
| Net income | -$128.55m | -$128.45m | -$127.55m | $70.13m |
News
8 latest- DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?Zacks · 4 days ago
- Denali (DNLI) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Denali Therapeutics Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Denali Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · 6 days ago
- Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Denali Gains Biotech Recognition As AVLAYAH Validates Blood-Brain Barrier Platform RTTNews · Oct 30, 2026
- Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?Zacks · Oct 14, 2026
- Denali Therapeutics Enters Oversold Territory (DNLI)BNK Invest · Oct 6, 2026
The company
Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- denalitherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.